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Abstract
Background: The prevalence of obesity and diabetes is increasing dramatically throughout the world. Studies have shown
that excess adiposity is a critical predictor of new onset T2DM. This meta-analysis is aimed to assess the metabolic effects of
fluoxetine in T2DM.
Methods and Findings: Electronic search was conducted in the database Medline, PubMed, EMBASE, and the Cochrane
library, from inception through to March 2011. A systematic review of the studies on the metabolic effects of fluoxetine in
T2DM was performed. The weighted mean difference (WMD) and its 95% CI were calculated from the raw data extracted
from the original literature. The software Review Manager (version 4.3.1) and Stata (version 11.0) were applied for meta-
analysis. Five randomized, placebo-controlled trials were included in the meta-analysis. According to WMD calculation,
fluoxetine therapy led to 4.27 Kg of weight loss (95%CI 2.58–5.97, P,0.000 01), 1.41 mmol/L of fasting plasma glucose (FPG)
decrement (95%CI 0.19–2.64, P=0.02) and 0.54 mmol/L of triglyceride (TG) reduction (95%CI 0.35–0.73, P,0.000 01)
compared with placebo. Moreover, fluoxetine therapy produced 0.78% of HbA1c decrement (95%CI 20.23–1.78). However,
this effect was not statistically significant (P=0.13).
Conclusions: Short period of fluoxetine therapy can lead to weight loss as well as reduction of FPG, HbA1c and TG in T2DM.
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Introduction
The prevalence of obesity and diabetes is increasing dramat-
ically throughout the world [1]. The global prevalence of diabetes
in 2010 was 284 million people worldwide constituting around
6.4% of the world population, which is higher than was projected
in earlier studies [2]. Furthermore, the projections for 2030 show
the prevalence to reach 439 million individuals comprising ,7.7%
of the world population [2]. The burden of diabetes on the world
economy has been rising steadily in the last decade to reach $376
billion in 2010 and is expected to reach $490 billion in 2030 [3].
From an epidemiologic point of view, the first relevant point is that
almost 80% of diabetes cases could be prevented just by avoiding
overweight and obesity [2]. The estimated attributable risk of
excess body weight is extremely high; no other modifiable effect
has such an impact on the health of the general population.
Studies have shown that excess adiposity is a critical predictor of
new onset type 2 diabetes [1,4,5,6]. It has been estimated that
every 1 kg increase in weight is associated with a relative 9%
increase in diabetes prevalence [7]. T2DM individuals with 20%–
30% above their ideal body weight have 2.5–3.0 fold higher
mortality than diabetic people at their ideal weight. Concerning
the patients of T2DM who are more than 40% above their ideal
weight, the mortality increases greater than five fold [8]. Adipose,
now recognized as an endocrine and secretory tissue, can release a
wide range of inflammation-related adipokines, which are
considered to play an important role in the development of
T2DM and metabolic syndrome [9,10].
Weight loss appears to be a more dominant predictor of
reduced diabetes incidence compared with changes in diet or
activity level [11,12,13]. The reduction of fat mass due to weight
loss can produce numerous benefits in T2DM, including improved
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21551glucose metabolism and increased insulin sensitivity [6,14,15,16].
These benefits are clinically meaningful only when the weight loss
is sustained over time. Based on the preceding observations,
weight control in type 2 diabetes has been recommended as an
early and important intervention [17,18,19].
Type 2 diabetic patients under lifestyle intervention will lose, on
average, 8% of initial body weight over 3–12 months [20].
However, most obese people regain their weight they have
successfully lost from dietary and behavioral treatment in long-
term outcome [21,22]. It seems difficult to achieve sustained
weight control in general population [20,23]. For Type 2 diabetic
patients, this issue is more complicated. Studies demonstrated that
diabetic patients lost less weight and regained their weight more
rapidly compared with the non-diabetic [24], which can be
attributed to the physiologic derangement and insulin treatment of
T2DM [25]. Hence, in the obese individuals for whom behavioral
therapy has failed, medical interventions such as weight-manage-
ment drugs are required in addition to the usual anti-diabetic
treatment. In general, pharmacologic therapy of obesity consists of
centrally acting appetite suppressants, drugs with a peripheral
effect on appetite, drugs that affect nutrient partitioning, and drugs
that increase thermogenesis. Several weight-loss medications have
been proved to be effective, and some have been applied in clinical
practice. However, only two drugs, orlistat and sibutramine, have
been approved by the US Food and Drug Administration (FDA) to
treat obesity long term, and both medications have undesirable
side effects, leaving an enormous unmet need for efficacious and
safe therapy for obesity.
Up to 20 percent of patients with diabetes have a major
depressive disorder [26]. Depression in patients with diabetes may
be associated with poor compliance with therapy [27], poor
glycemic control [28,29,30] and an increased risk of complications
[31,32]. As an inhibitor of serotonin re-uptake and one of the
world’s most prescribed antidepressants, fluoxetin leads to weight
loss by decreasing appetite and in turn inhibition of energy intake
[33,34]. However, data on fluoxetine are mainly available among
depressed patients and the results are not always consistent [35].
The current meta-analysis is aimed to systematically assess the
efficacy of fluoxetine for the treatment of T2DM, concerning the
existing studies eligible and available.
Materials and Methods
Systematical evaluation of the efficacy of fluoxetine to T2DM
was based on searching and data-analyzing of the published
random, placebo-controlled clinical trials. Body weight loss, fasting
plasma glucose, HbA1c, triglyceride and total cholesterol decre-
ment, were compared between fluoxetine and placebo group.
Then, the weighted mean difference (WMD) and its 95%
confidence interval (CI) were calculated.
Study inclusion criteria
1) Studies included should be published, regardless of its
research method, publication language or date. 2) Studies included
should be random, placebo-controlled trials. 3) The research
participants should be Type 2 diabetic patients. 4) WMD and its
95% CI could be calculated from the raw data extracted from the
original literature.
Search strategy
The literature search, as well as screening of titles, abstracts, and
full-text articles, was completed independently by two investiga-
tors, according to the inclusion criteria mentioned above.
Electronic search was conducted in the database Medline,
PubMed, EMBASE, and the Cochrane library, from inception
through to March 2011. The terms used for electronic search were
fluoxetine OR SSRI OR antidepressants and diabetes OR T2DM
OR type 2 diabetes OR obesity OR weight loss OR body weight.
Various combinations of the keywords were applied. Moreover,
the references of included literature were searched manually and
the Related articles provided by PubMed were screened.
Data extraction
Information from each study was extracted independently by
two investigators, using a standardized data extraction form. Any
dispute was solved unanimously via discussion. The literature
approved by both investigators could be included in this meta-
analysis. If two or more studies have shared research data, then the
study that has the largest amount of samples should be included,
while others be excluded. General characteristics of the study
(author, year of publication, country, study design, sample size),
characteristics of the study groups, their comparability on baseline
characteristics (age, sex), duration of treatment, BMI, and
outcomes (weight loss, fasting plasma glucose, HbA1c, total
cholesterol, triglyceride) were recorded, where available, and
double-checked. Where appropriate, an effort was made to
complete the data set through communication with the authors.
Statistical analysis
If chi-square test shows there is no significance of heterogenecity
among the included studies (P.0.10), then fixed model can be
applied to calculate WMD and its 95% CI. By contrast, if there is
significant heterogenecity among the included studies (P#0.10),
then random model should be applied to calculate WMD and its
95% CI. Finally, perform u-test of WMD. The statistics was
performed by the software RevMan 4.3.1. The software Stata
(version 11.0) was applied for meta-regression analysis.
Results
Search results
The search strategy identified 1230 potentially relevant studies,
fifteen of which were searched through reference sections of
relevant publications or manual search. A flow chart summarizing
search results is provided in Figure 1. One thousand one hundred
and twenty-one publications were excluded since it was clear from
the title that they did not fulfill the selection criteria. From the
remaining 109 publications, 60 reviews were excluded. Forty-nine
articles were read in full, independently by two investigators, to
assess their accordance with the predefined inclusion criteria.
Forty-four studies were excluded because they were performed
among depressed or obese participants. Finally, 5 studies were
included in the meta-analysis [36,37,38,39,40], all of which were
randomized, placebo-controlled and double-blind parallel clinical
trials.
Systemic review
General characteristics of the eligible studies were given in
Table 1. The participants were generally in poor glycemic control
[41]. Only one study included insulin-using patients, while the
other 4 excluded patients under insulin therapy [40]. The follow-
up interval ranged from 6 to 12 months in 4 studies, while the rest
one lasted only 2 months [36].
The previous medication treatment was maintained during the
follow-up interval. In O’Kane study, medications for obesity-
related problems, such as osteoarthritis of weight bearing joints,
hypertension, ischemic heart disease and varicose veins were
continued [38]. In Gray study, all subjects had been put on insulin
Fluoxetine in Adults with Type 2 Diabetes
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[40]. In Connolly study, all participants were diet controlled
T2DM. The previous treatment was maintained during the follow-
up interval, except medications that could alter weight, such as
steroids, appetite suppressants, anti-depressants, diuretics, and
thyroid hormone replacement [37]. In Breum study, those who
were taking medications that could alter body weight had been
excluded from the research. None of the participants received
insulin therapy [39]. In Daubresse study, the usual oral
hypoglycemic agent therapy was maintained during the rearch
[36]. Patients who were concurrently in treatment with other anti-
obese drugs had been excluded from all of the 5 studies.
The mean age of participants varied between different studies
and ranged from 44 to 67 years. Sex ratio was presented in 4
studies. The dosage of fluoxetine was highly consistent (60 mg
daily) among the 5 included studies. At the same time, the controls
received placebo in the 5 studies. Two studies involved a dietary
intervention for both the fluoxetine and placebo group [37,38].
None presented information of attrition rate. In the trial by
Daubresse, participants were selected only when they had good
compliance [36]. No studies discussed allocation concealment
(Table 2). Adverse events occurred in both fluoxetine and placebo
group. Tremor, sweating and somnolence were reported in very
few cases.
Meta-analysis
Body weight. All of the 5 studies reported body weight loss
due to fluoxetine. Heterogenecity test of the 5 studies suggested
random model be applied (P,0.000 1). According to WMD
Figure 1. Flow chart of the systematic review and meta-
analysis.
doi:10.1371/journal.pone.0021551.g001
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weight loss compared with placebo (95%CI 2.58–5.97, P,0.000
01).
Fasting plasma glucose. Four studies reported the decrease
of fasting plasma glucose (FPG) after fluoxetine therapy, while the
rest one claimed the reverse [36]. Heterogenecity test of the 5
studies suggested random model be applied (P,0.000 01).
According to WMD calculation (Figure 2), fluoxetine therapy
lead to 1.41 mmol/L of FPG decrement compared with placebo
(95%CI 0.19–2.64, P=0.02).
HbA1c. Four studies reported the decrease of HbA1c after
fluoxetine therapy, while the rest one claimed the reverse [36].
Heterogenecity test of the 5 studies suggested random model be
applied (P,0.000 01). According to WMD calculation (Figure 2),
fluoxetine therapy accounted for 0.78% of HbA1c decrement
compared with placebo (95%CI20.23–1.78). However, this effect
was not statistically significant (P=0.13).
Triglyceride. Two studies reported the decrease of
triglyceride (TG) after fluoxetine therapy [36], while one
claimed the reverse [36]. Heterogenecity test of the 3 studies
suggested fixed model be applied (P=0.23). According to WMD
calculation (Figure 2), fluoxetine therapy lead to 0.54 mmol/L of
TG decrement compared with placebo (95%CI 0.35–0.73,
P,0.000 01).
Total cholesterol. Three studies reported the increase of
total cholesterol (TC) after fluoxetine therapy [36]. Heterogenecity
test of the 3 studies suggested fixed model be applied (P=0.45).
According to WMD calculation (Figure 2), fluoxetine therapy lead
to 0.02 mmol/L of TC increment compared with placebo (95%CI
20.06–0.11). However, this effect was not statistically significant
(P=0.56).
Meta-regression
Using the net change in the fluoxetine group minus the placebo
group, we performed a meta-regression to investigate potential
interactions of weight loss, HbA1c, and FPG with study variables
including mean age of participants, gender distribution in
fluoxetine/placebo group, baseline BMI across studies and
fluoxetine/placebo conditions, and duration of treatment. How-
ever, none of the combinations approached significance (All
P.0.05).
Discussion
Earlier longer term trials with fluoxetine in obese patients
showed that the effect of drug on body weight is transient [42],
which lead to the discontinuation of the clinical development
program of fluoxetine as an anti-obesity drug. In recent years,
various adverse effects have been associated with orlistat and
sibutramine, two kinds of diet pills which are widely prescribed
throughout the world. Therefore, a lot of researchers begin to
focus again on fluoxetine [43]. In 2005, a review of pharmaco-
therapy for weight loss [44] included 6 trials, 4 [36,37,38,40] of
which are included in our work. Of the remaining 2 studies, one
studied both T2DM and prediabetes [45], while the other one
could not be identified through our search strategy. Moreover, the
previous review focused on body weight and HbA1c improvement,
while our work investigated more clinical variables such as FPG,
TC and TG. In another review by Serretti and Mandelli [35],
most of the included studies were not placebo-controlled, and
comparison with a composite placebo sample derived from other
studies was performed. They further demonstrated that estimates
from placebo and non-placebo controlled studies were not
different, which could probably interpreted by the potential bias
linked to the selection of studies. The current meta-analysis has,
for the first time, systematically identified and pooled a wide range
of evidence about the efficacy of fluoxetine in obese people with
T2DM.
In the 5 studies included in current meta-analysis, the
participants were not depressed patients complicated with diabetes
or obesity, but T2DM patients from diabetic clinic. Our analysis
demonstrated that fluoxetine produced significant and clinically
meaningful changes in body weight, FPG, HbA1c, triglyceride and
cholesterol in T2DM, which confirmed that the metabolic benefit
of fluoxetine was independent of its anti-depressive effect. Body
weight loss has positive effects on metabolic control in obese
patients with T2DM. Moreover, the metabolic benefits acquired
from pharmacotherapy can be sustainable after steady weight loss.
In the 5 included studies, few severe adverse events were reported.
Fluoxetine were generally well tolerated and produced a low
incidence of serious adverse events. By contrast, the use of orlistat
has been associated with lower levels of fat soluble vitamins and
supplementation, while sibutramine produced palpitations and a
nonsignificant increase in pulse rate [42]. Fluoxetine is effective
and safer in treating obesity with T2DM, compared with other
pharmacologic therapies.
In current meta-analysis, the treatment duration was up to 12
months. Therefore, the long-term effect of fluoxetine in obese
patients with T2DM is still unclear. However, a retrospective
cohort study has shown that the benefits of weight loss in T2DM
may be long-lasting [46]. Though considering psychiatric patients,
Serretti and Mandelli [42], showed a trend for an increase of
weight with fluoxetine in the medium-long term treatment.
Among the 5 studies, almost all of the participants are middle-
aged, who are generally in poor glycemic control. Since BMI was
reported, it was accurate to assess the degree of overweight. As the
participants might be intentionally selected, and some studies
eliminated the noncompliant participants, our analysis may have
selection bias, and should be considered appropriate only to
similar populations.
Table 2. Quality assessment of included studies.
Study Randomization
Allocation
concealment Blindness
Blindness
scheme ITT analysis Jadad score
Gray DS Yes, method unknown unknown double-blind unknown unknown 2
O’Kane M Yes, method unknown unknown double-blind unknown no 2
Breum L Yes, method unknown unknown double-blind unknown unknown 2
Connolly VM Yes, method unknown unknown double-blind unknown no 2
Daubresse JC Yes, method unknown unknown double-blind unknown unknown 2
doi:10.1371/journal.pone.0021551.t002
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doi:10.1371/journal.pone.0021551.g002
Fluoxetine in Adults with Type 2 Diabetes
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e21551Fluoxetine exhibited modest and significant weight loss effect.
Even moderate weight loss can lead to considerable blood pressure
and glucose improvement in obese patients with T2DM. In non-
diabetic populations, the efficacy of weight-loss drugs on body
weight is also modest, and the weight is easily regained after the
medication is discontinuated [47]. This phenomenon is more
obvious in diabetic patients, which may explain the small
reduction in weight noted in our analysis.
Fluoxetine showed statistically significant effects on FPG, which
is very meaningful because FPG is an important indicator that can
be related to the development of the disease. The trend towards
greater improvement in glycemic control with fluoxetine could not
be attributed simply to the effects of weight loss. It is possible that
fluoxetine affects other unmeasured characteristics, such as insulin
action.
Fluoxetine therapy led to significant reduction in triglyceride
levels in three studies [36,38,39]. The improvement of lipid
profiles is encouraging, given that they are associated with risk of
ischemic heart disease [48]. However, it remains unclear whether
the improved lipid profiles could be sustained in long-term period.
Concealing allocation was not mentioned in any study, nor did
the method of randomization. The method of sampling and
participant recruitment was rarely described, making it difficult to
conclude to whom the intervention can be applied.
In general practice, weight loss medications are usually
combined with various lifestyle modification [49]. However, no
study in current analysis examined the efficacy of pharmacother-
apy combined with lifestyle or behavioral interventions. Some
studies reported that addition of one kind of behavioral
intervention may improve the effectiveness of medication in the
obese [50].
It is noteworthy that T2DM is a progressive disease. If obesity is
not intervened, the disease will become more irreversible with
time. Therefore, various potential approaches of weight loss need
to be evaluated. While lifestyle modification alone is not enough,
weight loss pharmacotherapy should be applied in conjunction
with behavioral programs. Although in two trials of fluoxetine, the
follow-up duration lasted for almost one year [38,39], longer term
of follow-up and larger study population are needed.
Further work is needed to examine the combination of lifestyle
modification and pharmacotherapy in order to determine the
optimal dosage and sequence of the two kinds of intervention.
More concern should be attached on the progress of fluoxetine in
the treatment of obese with T2DM. The research is expected to
lead to the development of an effective, safe and long-term
pharmacotherapy for obese patients with T2DM.
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